| __timestamp | MorphoSys AG | Soleno Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 9689000 | 2917513 |
| Thursday, January 1, 2015 | 10431000 | 7878291 |
| Friday, January 1, 2016 | 9618000 | 8366794 |
| Sunday, January 1, 2017 | 12348000 | 6610381 |
| Monday, January 1, 2018 | 28310241 | 6556000 |
| Tuesday, January 1, 2019 | 59336147 | 6930000 |
| Wednesday, January 1, 2020 | 159145941 | 8758000 |
| Friday, January 1, 2021 | 199800000 | 10806000 |
| Saturday, January 1, 2022 | 90225000 | 9844000 |
| Sunday, January 1, 2023 | 92538000 | 13481000 |
Unleashing the power of data
In the ever-evolving landscape of biotechnology, effective cost management is crucial. MorphoSys AG and Soleno Therapeutics, Inc. offer a compelling study in contrasts. Over the past decade, MorphoSys AG has seen its Selling, General, and Administrative (SG&A) expenses skyrocket by over 850%, peaking in 2021. This surge reflects strategic investments in research and development, positioning the company for future growth. In contrast, Soleno Therapeutics, Inc. has maintained a more stable SG&A trajectory, with expenses increasing by approximately 360% since 2014. This steady approach underscores a focus on sustainable growth and operational efficiency. As of 2023, MorphoSys AG's SG&A expenses are nearly seven times higher than those of Soleno, highlighting differing strategic priorities. Understanding these trends provides valuable insights into how these companies navigate the financial demands of the biotech industry.
Breaking Down SG&A Expenses: Novo Nordisk A/S vs Soleno Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or MorphoSys AG
Selling, General, and Administrative Costs: AbbVie Inc. vs Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Amgen Inc. and Soleno Therapeutics, Inc.
Selling, General, and Administrative Costs: Regeneron Pharmaceuticals, Inc. vs Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Catalent, Inc. and Soleno Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and MorphoSys AG
Alkermes plc and MorphoSys AG: SG&A Spending Patterns Compared
Apellis Pharmaceuticals, Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? MorphoSys AG or Taro Pharmaceutical Industries Ltd.
Bausch Health Companies Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Amicus Therapeutics, Inc. and Soleno Therapeutics, Inc.: SG&A Spending Patterns Compared